Bladuril,
Flavoxate,
Flavoxate Hydrochloride,
Hydrochloride, Flavoxate,
Spasuret,
Urispas,
Uronid,
Flavoxate hydrochloride,
3717-88-2,
Flavoxate HCL,
Urispas,
DW-61,
Bladderon,
Peflate,
Spasmal,
Flavoxate (hydrochloride),
DW 61 (flavoxate),
NSC-114649,
UNII-9C05J6089W,
Flavoxate hydrochloride,
Rec 7/0040,
CHEBI:5089,
Rec-7-0040,
MFCD00072099,
2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate hydrochloride,
9C05J6089W,
Piperidinoethyl-3-methylflavone-8-carboxylate hydrochloride,
Spasuret hydrochloride,
2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride,
C24H26ClNO4,
DSSTox_CID_27764,
DSSTox_RID_82541,
DSSTox_GSID_47784,
Verrispasmin amp.,
3-Methyl-4-oxo-2-phenyl-4H-benzopyran-8-carboxylic acid 2-piperidinyl ethyl ester,
3-Methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid 2-(1-piperidinyl)ethyl ester hydrochloride,
AK 123,
NSC114649,
NCGC00016636-01,
CAS-3717-88-2,
flavoxate-hcl,
SR-01000872667,
2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate;hydrochloride,
Prestwick_884,
Flavoxate hydrochloride [USAN:USP:JAN],
AC1L9B0J,
Rec-7-0040 HCl,
MLS002154247,
SCHEMBL124540,
CHEMBL1200875,
DTXSID1047784,
CTK8B3835,
HY-B0549A,
KS-00000XSH,
AOB5638,
1-Piperidinoethanol, hydrochloride,
HMS1568B06,
BCP13298,
Tox21_110537,
ANW-43270,
s4027,
AKOS025310107,
Flavoxate hydrochloride (JP17/USAN),
Tox21_110537_1,
AC-1093,
API0002707,
CCG-220242,
CS-2652,
RL03419,
DW-61;Rec-7-0040;DW61,
NCGC00016636-05,
AN-15251,
AS-12321,
BC222362,
CC-28434,
SMR000499576,
ACM1189678430,
AB0011722,
TL8002737,
TR-015131,
F0717,
FT-0658191,
FT-0668549,
SW197005-3,
D00718,
J10335,
27814-EP2269989A1,
27814-EP2298767A1,
27814-EP2298772A1,
27814-EP2308839A1,
27814-EP2314587A1,
Flavoxate hydrochloride, >=98% (HPLC), solid,
C-34896,
J-521367,
SR-01000872667-1,
WLN: T66 BO EVJ CR& D1 JVO2- AT6NTJ &GH,
4H-1-Benzopyran-8-carboxylic acid, 2-piperidinoethyl ester, hydrochloride,
Flavoxate hydrochloride, European Pharmacopoeia (EP) Reference Standard,
Flavoxate hydrochloride, United States Pharmacopeia (USP) Reference Standard,
1-(2-{[(3-methyl-4-oxo-2-phenyl-4H-chromen-8-yl)carbonyl]oxy}ethyl)piperidinium chloride,
2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenyl-chromene-8-carboxylate hydrochloride,
2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate hydrochloride,
2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride,
4H-1-Benzopyran-8-carboxylic acid, 2-(1-piperidinyl)ethyl ester, hydrochloride,
flavoxate,
Spasuret,
Urispadol,
Genurin,
Urispas (TN),
CABAZITAXEL,
Flavoxate-d4 Hydrochloride,
CCRIS 1950,
C24H25NO4.ClH,
EINECS 223-066-4,
C24-H25-N-O4.Cl-H,
NSC 114649,
REC 7-0040,
Flavoxate hydrochloride [USAN:JAN],
CID441345,
ACN-040069,
CS-O-11651,
B3433,
1-Piperidineethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate, hydrochloride,
4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester, hydrochloride,
4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-piperidinoethyl ester, hydrochloride,
Flavoxate hydrochloride, 99%, a muscarinic AChR antagonist - 25G 25g,
183133-96-2,
895519-90-1,